With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...

Researchers reprogrammed bacterial bridge recombinases to edit large genomic regions in mammalian cells, revealing a ...

Wave is expecting feedback from US regulators on a path forward for WVE-006 as a potential alpha-1 antitrypsin deficiency therapy in mid-2026.

Detailed price information for Wave Life Sci Ord Sh (WVE-Q) from The Globe and Mail including charting and trades.

Wave Life Sciences has lost GSK as the partner for its RNA-editing drug for alpha-1 antitrypsin deficiency (AATD), just over ...

Life runs on instructions you never see. Every cell reads DNA, turns that message into RNA, and then builds proteins that ...

US biotech Wave Life Sciences has regained full rights to WVE-006 from British pharma GSK, bringing the RNA-editing therapy for alpha-1 antitrypsin deficiency back in-house as it prepares for ...

GSK returns rights to Wave's RNA editing program for AATD; Cassidy took on RFK Jr. over vaccines. Now Kennedy's followers are ...

After GSK’s return of Wave Life Sciences’ WVE-006 as well as the mid-stage failure of Korro Bio’s candidate, the alpha-1 ...

Ltd (NASDAQ:WVE) stock rose 2.1% Monday after the clinical-stage biotechnology company announced it has regained full rights to WVE-006, its investigational RNA editing therapy for alpha-1 antitrypsin ...

Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. | Wave Life Sciences has the fate of its lead RNA editing candidate back in its own hands. GSK has decided not ...

Wave claimed GSK is handing back rights to the frontrunning program not because of questions about its potential, but because ...